Management of HIV-infected patients with multidrug-resistant virus
- PMID: 16091231
- DOI: 10.1007/s11904-004-0017-8
Management of HIV-infected patients with multidrug-resistant virus
Abstract
Treatment-experienced patients with HIV may harbor virus that has accumulated several mutations conferring decreased susceptibility to one or more antiretroviral drugs. For clinicians treating these patients, identifying a tolerable antiretroviral regimen with a reasonable chance of a durable virologic effect represents a major challenge. The first priority is to identify and correct the mechanisms responsible for previous treatment failure. Resistance testing and drug level monitoring may be useful in this setting. The patient's history of antiretroviral drug tolerability, comorbidities, and concomitant medications should be considered. Patients embarking on multiple-drug regimens will require close monitoring for adherence, toxicities, and drug-drug interactions. The guiding principle when constructing a rescue or salvage regimen is to achieve a cumulative activity score greater than 2, recognizing that some agents will have only partial activity. Some new drugs are available that may be helpful if used carefully with an active background regimen.
Similar articles
-
An update and review of antiretroviral therapy.Pharmacotherapy. 2006 Aug;26(8):1111-33. doi: 10.1592/phco.26.8.1111. Pharmacotherapy. 2006. PMID: 16863488 Review.
-
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.Clin Infect Dis. 2009 Oct 15;49(8):1259-67. doi: 10.1086/605674. Clin Infect Dis. 2009. PMID: 19757993 Clinical Trial.
-
Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.AIDS Rev. 2004 Jul-Sep;6(3):123-30. AIDS Rev. 2004. PMID: 15595429 Review.
-
Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.J Chemother. 2008 Feb;20(1):143-4. doi: 10.1179/joc.2008.20.1.143. J Chemother. 2008. PMID: 18343760 No abstract available.
-
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.HIV Clin Trials. 2008 Jul-Aug;9(4):213-24. doi: 10.1310/hct0904-213. HIV Clin Trials. 2008. PMID: 18753116 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical